Takaesu Yoshikazu, Komada Yoko, Asaoka Shoichi, Kagimura Tatsuo, Inoue Yuichi
Department of Psychiatry, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
Department of Somnology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan; Japan Somnology Center, Neuropsychiatric Research Institute, 1-24-10 Yoyogi, Shibuya-ku, Tokyo, 151-0053, Japan.
PLoS One. 2014 Nov 19;9(11):e113753. doi: 10.1371/journal.pone.0113753. eCollection 2014.
This study investigated factors associated with long-term use of benzodiazepines (BZDs) or benzodiazepine receptor agonists (BzRAs) as hypnotics in patients with chronic insomnia. Consecutive patients (n = 140) with chronic insomnia were enrolled in this study (68 men and 72 women; mean age, 53.8 ± 10.8 years). All patients filled out a self-assessment questionnaire asking clinical descriptive variables at the baseline of the treatment period; patients received the usual dose of a single type of BZD or BzRA. The Pittsburgh Sleep Quality Index (PSQI) and the Zung Self-Rating Depression Scale were self-assessed at the baseline, and the former was re-evaluated at the time of cessation of medication or at the end of the 6-month treatment period. The PSQI included the following sub-items: evaluating sleep quality (C1), sleep latency (C2), sleep duration (C3), habitual sleep efficiency (C4), frequency of sleep disturbance (C5), use of sleeping medication (C6), and daytime dysfunction (C7). Among the patients, 54.6% needed to continue hypnotics for a 6-month treatment period. Logistic regression analysis revealed that, among descriptive variables, only the PSQI score appeared as a significant factor associated with long-term use {odds ratio (OR) = 2.8, 95% confidence interval (CI) = 2.0-4.0}. The receiver operating curve (ROC) analysis identified that the cut-off PSQI total score at the baseline for predicting long-term use was estimated at 13.5 points (area under the curve = 0.86, 95% CI = 0.8-0.92). Among the sub-items of PSQI, the increases in C1: (OR = 8.4, 95% CI = 2.4-30.0), C3: (OR = 3.6, 95% CI = 1.1-11.5), C4: (OR = 11.1, 95% CI = 3.6-33.9), and C6: (OR = 3.4, 95% CI = 1.9-6.2) scores were associated with long-term use. This study revealed that a high PSQI score at the baseline, particularly in the sub-items relating to sleep maintenance disturbance, is predictive of long-term hypnotic treatment. Our results imply the limitation of the effectiveness of hypnotic treatment alone for chronic insomnia.
本研究调查了慢性失眠患者长期使用苯二氮䓬类药物(BZD)或苯二氮䓬受体激动剂(BzRA)作为催眠药的相关因素。本研究纳入了140例连续的慢性失眠患者(男性68例,女性72例;平均年龄53.8±10.8岁)。所有患者在治疗期基线时填写一份自我评估问卷,询问临床描述性变量;患者接受单一类型BZD或BzRA的常规剂量治疗。匹兹堡睡眠质量指数(PSQI)和zung自评抑郁量表在基线时进行自我评估,前者在停药时或6个月治疗期结束时重新评估。PSQI包括以下子项目:评估睡眠质量(C1)、入睡潜伏期(C2)、睡眠时间(C3)、习惯性睡眠效率(C4)、睡眠干扰频率(C5)、使用助眠药物(C6)和日间功能障碍(C7)。在这些患者中,54.6%的患者在6个月治疗期内需继续使用催眠药。逻辑回归分析显示,在描述性变量中,只有PSQI评分是与长期使用相关的显著因素{比值比(OR)=2.8,95%置信区间(CI)=2.0-4.0}。受试者工作特征曲线(ROC)分析确定,预测长期使用的基线PSQI总分临界值估计为13.5分(曲线下面积=0.86,95%CI=0.8-0.92)。在PSQI的子项目中,C1:(OR=8.4,95%CI=2.4-30.0)、C3:(OR=3.6,95%CI=1.1-11.5)、C4:(OR=11.1,95%CI=3.6-33.9)和C6:(OR=3.4,95%CI=1.9-6.2)评分的增加与长期使用相关。本研究表明,基线时PSQI评分较高,尤其是与睡眠维持障碍相关的子项目,可预测长期催眠治疗。我们的结果提示单纯催眠治疗对慢性失眠有效性的局限性。